Association of frequent hypermethylation with high grade histological subtype in lung adenocarcinoma
Authors:
Open Access
- 21 April 2023
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 114 (7) , 3003-3013
Abstract
Lung adenocarcinoma is classified morphologically into five histological subtypes according to the WHO classification. While each histological subtype correlates with a distinct prognosis, the molecular basis has not been fully elucidated. Here we conducted DNA methylation analysis of 30 lung adenocarcinoma cases annotated with the predominant histological subtypes and three normal lung cases using the Infinium BeadChip. Unsupervised hierarchical clustering analysis revealed three subgroups with different methylation levels: high‐, intermediate‐, and low‐methylation epigenotypes (HME, IME, and LME). Micropapillary pattern (MPP)‐predominant cases and those with MPP components were significantly enriched in HME (p = 0.02 and p = 0.03, respectively). HME cases showed a significantly poor prognosis for recurrence‐free survival (p < 0.001) and overall survival (p = 0.006). We identified 365 HME marker genes specifically hypermethylated in HME cases with enrichment of “cell morphogenesis” related genes; 305 IME marker genes hypermethylated in HME and IME, but not in LME, with enrichment “embryonic organ morphogenesis”‐related genes; 257 Common marker genes hypermethylated commonly in all cancer cases, with enrichment of “regionalization”‐related genes. We extracted surrogate markers for each epigenotype and designed pyrosequencing primers for five HME markers (TCERG1L, CXCL12, FAM181B, HOXA11, GAD2), three IME markers (TBX18, ZNF154, NWD2) and three Common markers (SCT, GJD2, BARHL2). DNA methylation profiling using Infinium data was validated by pyrosequencing, and HME cases defined by pyrosequencing results also showed the worse recurrence‐free survival. In conclusion, lung adenocarcinomas are stratified into subtypes with distinct DNA methylation levels, and the high‐methylation subtype correlated with MPP‐predominant cases and those with MPP components and showed a poor prognosis.Keywords
Funding Information
- Chiba University (Global Prominent Research grant 2018‐Y9, IAAR Research Support Program)
- Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control 19ck0106263h0003)
This publication has 48 references indexed in Scilit:
- DNA Methylation Pyrosequencing Assay Is Applicable for the Assessment of Epigenetic Active Environmental or Clinical Relevant ChemicalsBioMed Research International, 2013
- Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or SmallerJNCI: Journal of the National Cancer Institute, 2013
- DNA Methylation Biomarkers Offer Improved Diagnostic Efficiency in Lung CancerCancer Research, 2012
- Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expressionGenome Research, 2012
- DNA methylation biomarker candidates for early detection of colon cancerTumor Biology, 2012
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCancer Discovery, 2011
- E‐cadherin transcriptional down‐regulation by epigenetic and microRNA‐200 family alterations is related to mesenchymal and drug‐resistant phenotypes in human breast cancer cellsInternational Journal of Cancer, 2010
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genomeNature Genetics, 2007
- The history of cancer epigeneticsNature Reviews Cancer, 2004